Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.

Agarwal R, Dawson MA, Dreyling M, Tam CS.

Leuk Lymphoma. 2018 Jun 18:1-13. doi: 10.1080/10428194.2018.1457148. [Epub ahead of print]

PMID:
29912596
2.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Future Oncol. 2018 Jun 5. doi: 10.2217/fon-2018-0163. [Epub ahead of print]

3.

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.

Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA.

Blood Rev. 2018 Apr 23. pii: S0268-960X(17)30158-3. doi: 10.1016/j.blre.2018.04.007. [Epub ahead of print] Review.

PMID:
29709246
4.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

PMID:
29590547
5.

Differential metabolic effects of constant moderate versus high intensity interval training in high-fat fed mice: possible role of muscle adiponectin.

Martinez-Huenchullan SF, Maharjan BR, Williams PF, Tam CS, Mclennan SV, Twigg SM.

Physiol Rep. 2018 Feb;6(4). doi: 10.14814/phy2.13599.

6.

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, Trotman J, Gasiorowski R.

Haematologica. 2018 May;103(5):e223-e225. doi: 10.3324/haematol.2017.186817. Epub 2018 Feb 8. No abstract available.

7.

Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.

Kuss BJ, Tam CS.

Intern Med J. 2017 Dec;47 Suppl 6:5-10. doi: 10.1111/imj.13680. Review.

PMID:
29250930
8.

Intramyocellular Lipid Droplet Size Rather Than Total Lipid Content is Related to Insulin Sensitivity After 8 Weeks of Overfeeding.

Covington JD, Johannsen DL, Coen PM, Burk DH, Obanda DN, Ebenezer PJ, Tam CS, Goodpaster BH, Ravussin E, Bajpeyi S.

Obesity (Silver Spring). 2017 Dec;25(12):2079-2087. doi: 10.1002/oby.21980. Epub 2017 Oct 25.

9.

Ibrutinib may impair serological responses to influenza vaccination.

Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS.

Haematologica. 2017 Oct;102(10):e397-e399. doi: 10.3324/haematol.2017.164285. Epub 2017 Jun 28. No abstract available.

10.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

11.

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS.

Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. Review.

PMID:
28504030
12.

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.

Butler LA, Tam CS, Seymour JF.

Blood Rev. 2017 Sep;31(5):318-327. doi: 10.1016/j.blre.2017.05.002. Epub 2017 May 3. Review.

PMID:
28499646
13.

Utility and reliability of non-invasive muscle function tests in high-fat-fed mice.

Martinez-Huenchullan SF, McLennan SV, Ban LA, Morsch M, Twigg SM, Tam CS.

Exp Physiol. 2017 Jul 1;102(7):773-778. doi: 10.1113/EP086328. Epub 2017 Jun 1.

PMID:
28497900
14.

The emerging role of skeletal muscle extracellular matrix remodelling in obesity and exercise.

Martinez-Huenchullan S, McLennan SV, Verhoeven A, Twigg SM, Tam CS.

Obes Rev. 2017 Jul;18(7):776-790. doi: 10.1111/obr.12548. Epub 2017 May 5. Review.

PMID:
28474421
15.

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Tam CS, Seymour JF.

Ann Oncol. 2017 May 1;28(5):920-921. doi: 10.1093/annonc/mdx103. No abstract available.

PMID:
28379289
16.

The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.

Kostos L, Chai KL, Tam CS, Bazargan A.

Leuk Lymphoma. 2017 Nov;58(11):2720-2723. doi: 10.1080/10428194.2017.1281414. Epub 2017 Mar 23. No abstract available.

PMID:
28332891
17.

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.

Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, Chan YC, Wong SQ, Silva MJ, Vedururu R, Doig K, Lam E, Arnau GM, Semple T, Wall M, Zivanovic A, Agarwal R, Petrone P, Jones K, Westerman D, Blombery P, Seymour JF, Papenfuss AT, Dawson MA, Tam CS, Dawson SJ.

Nat Commun. 2017 Mar 17;8:14756. doi: 10.1038/ncomms14756.

18.

Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?

Handunnetti SM, Polliack A, Tam CS.

Leuk Lymphoma. 2017 Jun;58(6):1281-1282. doi: 10.1080/10428194.2017.1298756. No abstract available.

PMID:
28271951
19.

Novel agents versus chemotherapy as frontline treatment of CLL.

Piggin A, Bayly E, Tam CS.

Leuk Lymphoma. 2017 Jun;58(6):1320-1324. doi: 10.1080/10428194.2017.1280606. Epub 2017 Feb 6. Review.

PMID:
28271950
20.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

21.

Skeletal muscle extracellular matrix remodeling after short-term overfeeding in healthy humans.

Tam CS, Chaudhuri R, Hutchison AT, Samocha-Bonet D, Heilbronn LK.

Metabolism. 2017 Feb;67:26-30. doi: 10.1016/j.metabol.2016.10.009. Epub 2016 Oct 28.

PMID:
28081775
22.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

PMID:
28076910
23.

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F.

Br J Haematol. 2016 Nov;175(3):462-466. doi: 10.1111/bjh.14324. Epub 2016 Sep 9.

PMID:
27611233
24.

Does weight cycling promote obesity and metabolic risk factors?

Mackie GM, Samocha-Bonet D, Tam CS.

Obes Res Clin Pract. 2017 Mar - Apr;11(2):131-139. doi: 10.1016/j.orcp.2016.10.284. Epub 2016 Oct 20. Review.

PMID:
27773644
25.

Raised FGF-21 and Triglycerides Accompany Increased Energy Intake Driven by Protein Leverage in Lean, Healthy Individuals: A Randomised Trial.

Gosby AK, Lau NS, Tam CS, Iglesias MA, Morrison CD, Caterson ID, Brand-Miller J, Conigrave AD, Raubenheimer D, Simpson SJ.

PLoS One. 2016 Aug 18;11(8):e0161003. doi: 10.1371/journal.pone.0161003. eCollection 2016.

26.

Energy Metabolic Adaptation and Cardiometabolic Improvements One Year After Gastric Bypass, Sleeve Gastrectomy, and Gastric Band.

Tam CS, Redman LM, Greenway F, LeBlanc KA, Haussmann MG, Ravussin E.

J Clin Endocrinol Metab. 2016 Oct;101(10):3755-3764. Epub 2016 Aug 4.

PMID:
27490919
27.

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Cheah CY, Joske D, Cull G, Gilbertson M, Opat SS, Tam CS, Wirth A, Seymour JF.

Br J Haematol. 2017 Sep;178(6):991-994. doi: 10.1111/bjh.14187. Epub 2016 Jul 29. No abstract available.

PMID:
27470657
28.

Maintenance therapy in CLL: resolving the controversy.

Tam CS.

Lancet Haematol. 2016 Jul;3(7):e304-5. doi: 10.1016/S2352-3026(16)30046-1. Epub 2016 Jun 16. No abstract available.

PMID:
27374461
29.

Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation.

Chan KL, Lokan J, Tam CS, Lew TE, Prince HM.

Leuk Lymphoma. 2017 Jan;58(1):207-210. Epub 2016 Jun 21. No abstract available.

PMID:
27326828
30.

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Chan KL, Blombery P, Jones K, Lade S, Carney D, Tran H, Seymour JF, Tam CS.

Br J Haematol. 2017 Apr;177(2):324-328. doi: 10.1111/bjh.14062. Epub 2016 May 15. No abstract available.

PMID:
27196127
31.

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Tam CS, Seymour JF, Roberts AW.

Semin Oncol. 2016 Apr;43(2):274-9. doi: 10.1053/j.seminoncol.2016.02.014. Epub 2016 Feb 6. Review.

PMID:
27040706
32.

Mechanisms of metabolism, aging and obesity.

Floyd ZE, Gawronska-Kozak B, Tam CS, Gimble JM.

Biochimie. 2016 May;124:1-2. doi: 10.1016/j.biochi.2016.03.005. Epub 2016 Mar 17. No abstract available.

PMID:
26995405
33.

Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Tam CS, Kamel S.

Haematologica. 2016 Mar;101(3):e123. doi: 10.3324/haematol.2015.139030. No abstract available.

34.

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.

Tam CS, Kimber T, Seymour JF.

Br J Haematol. 2017 Mar;176(5):829-831. doi: 10.1111/bjh.14000. Epub 2016 Feb 25. No abstract available.

PMID:
26915463
35.

Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo-obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion.

Braude MR, Trubiano JA, Heriot A, Dickinson M, Carney D, Seymour JF, Tam CS.

Intern Med J. 2016 Feb;46(2):238-9. doi: 10.1111/imj.12977. No abstract available.

PMID:
26899893
36.

Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.

Tam CS, Polliack A.

Leuk Lymphoma. 2016;57(6):1247-8. doi: 10.3109/10428194.2015.1137294. Epub 2016 Feb 17. No abstract available.

PMID:
26732524
37.

The effects of high-fat feeding on physical function and skeletal muscle extracellular matrix.

Tam CS, Power JE, Markovic TP, Yee C, Morsch M, McLennan SV, Twigg SM.

Nutr Diabetes. 2015 Dec 14;5:e187. doi: 10.1038/nutd.2015.39.

38.

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators.

N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.

39.

Energy Adaptations Persist 2 Years After Sleeve Gastrectomy and Gastric Bypass.

Tam CS, Rigas G, Heilbronn LK, Matisan T, Probst Y, Talbot M.

Obes Surg. 2016 Feb;26(2):459-63. doi: 10.1007/s11695-015-1972-4.

PMID:
26637359
40.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.

Blood. 2016 Jan 21;127(3):303-9. doi: 10.1182/blood-2015-09-667675. Epub 2015 Oct 22.

41.

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.

Lew TE, Cheah CY, Carney DA, Prince HM, Wolf M, Bazargan A, Januszewicz EH, Filshie R, Westerman D, Seymour JF, Tam CS.

Leuk Lymphoma. 2016 May;57(5):1044-53. doi: 10.3109/10428194.2015.1096353. Epub 2015 Nov 20.

PMID:
26464106
42.

Myokine Expression in Muscle and Myotubes in Response to Exercise Stimulation.

Covington JD, Tam CS, Bajpeyi S, Galgani JE, Noland RC, Smith SR, Redman LM, Ravussin E.

Med Sci Sports Exerc. 2016 Mar;48(3):384-90. doi: 10.1249/MSS.0000000000000787.

43.

A novel way to consolidate incomplete responses in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Tam CS, Polliack A.

Leuk Lymphoma. 2016;57(3):503-4. doi: 10.3109/10428194.2015.1096358. Epub 2015 Oct 15. No abstract available.

PMID:
26390065
44.

Predictors of weight loss 2 years after laparoscopic sleeve gastrectomy.

Martin DJ, Lee CM, Rigas G, Tam CS.

Asian J Endosc Surg. 2015 Aug;8(3):328-32. doi: 10.1111/ases.12193. Epub 2015 Apr 30.

PMID:
25929176
45.

Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Arana Yi C, Tam CS, Verstovsek S.

Future Oncol. 2015;11(5):719-33. doi: 10.2217/fon.14.272. Review.

46.

How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?

Tam CS, Stilgenbauer S.

Leuk Lymphoma. 2015 Mar;56(3):587-93. doi: 10.3109/10428194.2015.1011641. Epub 2015 Feb 17. Review.

PMID:
25641428
47.

Association between early peak temperature and mortality in neutropenic sepsis.

Weinkove R, Bailey M, Bellomo R, Saxena MK, Tam CS, Pilcher DV, Beasley R, Young PJ.

Ann Hematol. 2015 May;94(5):857-64. doi: 10.1007/s00277-014-2273-z. Epub 2014 Dec 18.

PMID:
25516454
48.

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS.

Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272. No abstract available.

49.

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.

Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, Bajel A, van Hal SJ, Chen SC, Milliken ST, Morrissey CO, Tam CS, Szer J, Weinkove R, Slavin MA.

Intern Med J. 2014 Dec;44(12b):1283-97. doi: 10.1111/imj.12595. Review.

PMID:
25482741
50.

Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.

van Hal SJ, Gilroy NM, Morrissey CO, Worth LJ, Szer J, Tam CS, Chen SC, Thursky KA, Slavin MA.

Intern Med J. 2014 Dec;44(12b):1277-82. doi: 10.1111/imj.12594. Review.

PMID:
25482740

Supplemental Content

Support Center